Results 161 to 170 of about 19,462,706 (409)

Pathogen-based precision medicine for drug-resistant tuberculosis

open access: gold, 2018
Matthias I. Gröschel   +5 more
openalex   +2 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Framework to prioritize health outcomes of particulate matter exposure using national claims data. [PDF]

open access: yesPLoS One
Heo J   +11 more
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Retracted: Clinical Evaluation of Unilateral Vertebroplasty for OVCF

open access: yesEmergency Medicine International, 2023
Emergency Medicine International
doaj   +1 more source

Home - About - Disclaimer - Privacy